"Fatty Liver" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Descriptor ID |
D005234
|
| MeSH Number(s) |
C06.552.241
|
| Concept/Terms |
Steatohepatitis- Steatohepatitis
- Steatohepatitides
- Steatosis of Liver
- Visceral Steatosis
- Steatoses, Visceral
- Steatosis, Visceral
- Visceral Steatoses
- Liver Steatosis
- Liver Steatoses
- Steatoses, Liver
- Steatosis, Liver
|
Below are MeSH descriptors whose meaning is more general than "Fatty Liver".
Below are MeSH descriptors whose meaning is more specific than "Fatty Liver".
This graph shows the total number of publications written about "Fatty Liver" by people in this website by year, and whether "Fatty Liver" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 2 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 5 | 0 | 5 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 5 | 8 |
| 2012 | 4 | 3 | 7 |
| 2013 | 3 | 2 | 5 |
| 2014 | 2 | 1 | 3 |
| 2015 | 3 | 2 | 5 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 4 | 2 | 6 |
| 2024 | 5 | 2 | 7 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fatty Liver" by people in Profiles.
-
GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic ß-cell function in obese male mice. Nat Commun. 2025 May 21; 16(1):4714.
-
Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025 Mar 06; 11(1):14.
-
Risk Stratification for Chronic Kidney Disease After Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Cirrhosis: Results From the NailMASH Consortium. Transplantation. 2025 03 01; 109(3):484-495.
-
Contemporary Ethical Considerations for Pediatric Metabolic and Bariatric Surgery. J Pediatr Surg. 2025 Mar; 60(3):161988.
-
Variance Between Clinical Guidance and Real-World Management of Metabolic Dysfunction-associated Steatotic Liver Disease in the United States. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):374-376.e3.
-
The clinical and economic burdens of metabolic dysfunction-associated steatohepatitis. J Med Econ. 2024 Jan-Dec; 27(1):919-930.
-
Genetic Background Strongly Influences the Impact of Carrying the Thr92Ala-DIO2 Polymorphism in the Male Mouse. Endocrinology. 2024 May 27; 165(7).
-
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgrad Med. 2024 Apr; 136(3):229-245.
-
Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake - Authors' reply. Lancet Gastroenterol Hepatol. 2024 May; 9(5):409-410.
-
Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction. Nat Med. 2024 Apr; 30(4):933-936.